Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCGO NASDAQ:FLGT NASDAQ:INNV NASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCGODocGo$1.33-2.2%$1.50$1.23▼$5.68$138.70M0.97459,240 shs568,763 shsFLGTFulgent Genetics$18.53+7.9%$19.66$14.57▼$25.11$523.02M0.83260,693 shs1.08 million shsINNVInnovAge$3.13-5.7%$3.93$2.60▼$6.69$448.24M0.5144,985 shs34,983 shsPSNLPersonalis$5.39-1.6%$6.06$2.81▼$7.79$484.02M1.861.04 million shs853,203 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCGODocGo-2.21%-8.90%-15.29%-42.42%-63.36%FLGTFulgent Genetics+7.86%+0.87%-7.81%-9.79%-22.57%INNVInnovAge-5.72%-18.49%-24.58%-0.63%-50.16%PSNLPersonalis-1.64%-16.95%-28.23%+29.57%+56.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCGODocGo2.7372 of 5 stars3.33.00.00.02.72.50.6FLGTFulgent Genetics4.1516 of 5 stars3.32.00.04.12.93.30.6INNVInnovAge1.7933 of 5 stars2.83.00.00.00.01.70.6PSNLPersonalis3.8386 of 5 stars3.51.00.04.21.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCGODocGo 2.50Moderate Buy$3.56167.67% UpsideFLGTFulgent Genetics 2.50Moderate Buy$24.0029.52% UpsideINNVInnovAge 1.50Reduce$5.0059.74% UpsidePSNLPersonalis 3.00Buy$7.6742.24% UpsideCurrent Analyst Ratings BreakdownLatest DCGO, PSNL, FLGT, and INNV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCGODocGo$520.50M0.26$0.41 per share3.22$3.09 per share0.43FLGTFulgent Genetics$283.47M1.99N/AN/A$36.92 per share0.50INNVInnovAge$763.85M0.55N/AN/A$2.04 per share1.53PSNLPersonalis$84.61M5.63N/AN/A$2.87 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCGODocGo$19.99M-$0.02N/A16.63N/A-0.12%2.52%1.70%8/7/2025 (Estimated)FLGTFulgent Genetics-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%N/AINNVInnovAge-$21.34M-$0.23N/A52.17N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)PSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/5/2025 (Confirmed)Latest DCGO, PSNL, FLGT, and INNV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DCGODocGo-$0.06N/AN/AN/A$77.58 millionN/A8/5/2025Q2 2025PSNLPersonalis-$0.25N/AN/AN/A$20.12 millionN/A5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 million5/6/2025Q3 2025INNVInnovAge-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCGODocGoN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AINNVInnovAgeN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCGODocGoN/A2.442.44FLGTFulgent GeneticsN/A6.326.32INNVInnovAge0.040.780.78PSNLPersonalisN/A6.916.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCGODocGo56.44%FLGTFulgent Genetics48.06%INNVInnovAge12.26%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipDCGODocGo2.70%FLGTFulgent Genetics31.76%INNVInnovAge1.40%PSNLPersonalis3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCGODocGo4,407101.98 million99.23 millionOptionableFLGTFulgent Genetics1,31330.44 million20.78 millionOptionableINNVInnovAge2,350135.01 million133.12 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableDCGO, PSNL, FLGT, and INNV HeadlinesRecent News About These CompaniesAnalyzing Personalis (NASDAQ:PSNL) and Assembly Biosciences (NASDAQ:ASMB)1 hour ago | americanbankingnews.comPersonalis, Inc. (NASDAQ:PSNL) Receives $7.67 Average Price Target from BrokeragesAugust 1 at 2:01 AM | americanbankingnews.comPersonalis (NASDAQ:PSNL) Shares Down 7.4% - What's Next?July 30 at 5:01 PM | marketbeat.comPersonalis (PSNL) Projected to Post Earnings on TuesdayJuly 30 at 9:35 AM | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Buy" from AnalystsJuly 29, 2025 | marketbeat.comARK Investment Management LLC Has $25.23 Million Stake in Personalis, Inc. (NASDAQ:PSNL)July 27, 2025 | marketbeat.comNikko Asset Management Americas Inc. Sells 57,339 Shares of Personalis, Inc. (NASDAQ:PSNL)July 27, 2025 | marketbeat.comPersonalis to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | businesswire.comPersonalis, Inc. (NASDAQ:PSNL) Stake Lifted by AIGH Capital Management LLCJuly 22, 2025 | marketbeat.comPersonalis, Inc. (PSNL) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comPersonalis Expands Tempus Strategic Collaboration to Bring Ultra ...July 11, 2025 | morningstar.comMPersonalis and Tempus extend cancer detection collaboration to 2029July 11, 2025 | investing.comPersonalis (NASDAQ:PSNL) Shares Down 6.1% - Time to Sell?July 10, 2025 | marketbeat.comPersonalis, Tempus Expand Detection Test to Include Colorectal CancerJuly 9, 2025 | marketwatch.comStocks to Watch: Nurix Therapeutics, Personalis, WK KelloggJuly 9, 2025 | marketwatch.comPersonalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer PatientsJuly 9, 2025 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Stake Lessened by Sumitomo Mitsui Trust Group Inc.July 5, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Buy" by BrokeragesJuly 4, 2025 | marketbeat.comPersonalis (NASDAQ:PSNL) Trading Down 3.5% - Here's WhyJuly 3, 2025 | marketbeat.comPersonalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?July 3, 2025 | zacks.comPersonalis (NASDAQ:PSNL) Hits New 12-Month High - Here's WhyJuly 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCGO, PSNL, FLGT, and INNV Company DescriptionsDocGo NASDAQ:DCGO$1.33 -0.03 (-2.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Fulgent Genetics NASDAQ:FLGT$18.53 +1.35 (+7.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.52 -0.02 (-0.08%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.InnovAge NASDAQ:INNV$3.13 -0.19 (-5.72%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.14 +0.02 (+0.48%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.Personalis NASDAQ:PSNL$5.39 -0.09 (-1.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.34 -0.05 (-0.95%) As of 08/1/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
